CHARDAN HEALTHCARE CONFERENCE - PRELUDE THERAPEUTICS INC

Explicit Guidance:

• Capital/Financing: Anticipates receiving $100 million in non-dilutive financing contingent on Insight exercising an option; clarity on this outcome expected in the first half of 2027.
• R&D Milestones (Timeline):
  • Q2 2026: JAK2 program advanced to clinic (already executed).
  • H1 2027: IND clearance for CAT6 program secured; patient enrollment anticipated "fairly soon."
  • H2 2027: Expected release of initial proof-of-concept (PoC) data for the CAT6 degrader program in breast cancer.
• Clinical Strategy: Protocol for the CAT6 program includes assessing monotherapy activity, safety, and early combination with fulvestrant.

Business-Segment Outlook:

• CAT6 Degraders (Breast Cancer): Positioning to target ER-positive (HR+) breast cancer where CAT6A is amplified and overexpressed. Differentiation strategy focuses on moving from second/third line (like competitors) to frontline therapy by combining with CDK4-6 inhibitors.
• JAK2/Melanocytic Neoplasia: Targeting the JAK2 JH2 program for the MPN (Myeloproliferative Neoplasia) community; program is clinically validated and active.
• MCALR Program: Identified as an important target for the MPN community; advancement in progress alongside other core programs.
• Pipeline Progress: Shift from "shelved" SPARCA program to focused execution on three validated targets (JAK2, CAT6, MCALR).

Market and Competitive Outlook:

• Differentiation vs. Competitors (Pfizer, Olema):
  • Selectivity: Competitors (Pfizer, Olema) are dual inhibitors targeting both CAT6A and CAT6B. Prelude's approach is a CAT6A-selective degrader, theoretically offering >1,000-fold selectivity via ternary complex formation, sparing CAT6B to improve therapeutic index.
  • Efficacy Profile: Anticipates "complete regressions" in preclinical models (vs. "tumor stasis" seen with inhibitors) and deeper biological impact by degrading the CAT6 complex.
  • Safety/Combination: Anticipates reduced neutropenia compared to dual inhibitors (which have dose-limiting toxicity and require "dose holidays" in >50% of patients), enabling combination with CDK4-6 inhibitors that also cause neutropenia.
  • Pricing/Market Share: Implicit goal is capturing market share in the frontline setting for ER+ breast cancer, a segment currently unaddressed by competitors due to tolerability constraints.

Macro / Industry Outlook:

• Competitive Landscape: Acknowledges that competitors (Pfizer) may reach the market first; however, the firm views the competitive advantage as lying in combinability and tolerability rather than speed to market for monotherapy.
• Regulatory/Development: IND clearance for CAT6 received; no specific regulatory hurdles mentioned other than standard clinical trial execution.

Strategic Initiatives:

• M&A/Partnerships: Potential $100 million financing event tied to Insight's option exercise in H1 2027; this acts as a critical catalyst for program advancement.
• R&D Focus: Execution pivot to three core programs (JAK2, CAT6, MCALR) with specific timeline deliverables for 2026–2027.
• Molecule Optimization: Use of structure-based design to target the 617F deep pocket in JAK2, achieving potency and selectivity where previous attempts (e.g., Insight) struggled with PK profiles.

Risks and Headwinds to Outlook:

• Clinical Success: Preclinical data (PDX/CDX models showing complete regressions) has not yet been verified in humans; clinical translation remains unproven.
• Toxicity Uncertainty: While preclinical data suggests sparing CAT6B mitigates neutropenia, the company admits "you have to do the clinical study to know that... translates."
• Competitor Speed: Competitors (Pfizer, etc.) may commercialize dual inhibitors first, potentially setting standards or limiting patient pools before Prelude's differentiated product launches.
• Financing Dependency: The $100 million financing is contingent on a third-party (Insight) option exercise; failure to exercise would delay or halt progression.
• Selectivity Metrics: Selectivity claims (10x vs 5x or 100x) rely on specific cell line panels and assay methods; cross-comparison with competitors (who have not released structures) is limited.

Management Tone on the Future:

• Confidence Level: Confident in the biological rationale ("strong role," "compelling" preclinical data) and the potential for deeper efficacy via degradation.
• Hedges: Repeatedly emphasizes that clinical studies are the ultimate arbiter ("you have to do the clinical study," "we'll test it in the clinic").
• Prioritization: Shifted from speculative exploration to focused "execution" on clinically validated targets.
• Timeline Certainty: High confidence on the 2027 timeline for financing clarity and PoC data, framing the next 12-18 months as a two-half roadmap.

Miscellaneous:

• Target Biology: CAT6A drives estrogen signaling, MEK regulation, and cell cycle genes; CAT6B is implicated in bone marrow development (sparing it is key to safety).
• JAK2 Mechanism: The "617F" mutation holds JAK2 in an active confirmation; the company's small molecules reverse this to an inactive state.
• Competitor Specifics: Insight (JAK2) struggled with PK profiles; Pfizer (CAT6) sees ~10% monotherapy response and 30% combo response but suffers from neutropenia.